BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates With ORLADEYO (Berotralstat)
Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $20
BioCryst to Report Third Quarter 2024 Financial Results on November 4
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking
BioCryst's ORLADEYO Reduces Hospital Visits and Emergency Care for Hereditary Angioedema Patients, Study Shows
Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, Including ORLADEYO (Berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16
Express News | BioCryst Pharmaceuticals Inc - Initial Trial Results Expected by End of 2025
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
Express News | BioCryst Begins Enrollment in Phase 1 Trial Evaluating Bcx17725, a Klk5 Inhibitor, for the Treatment of Netherton Syndrome
With 80% Institutional Ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is a Favorite Amongst the Big Guns
Express News | BioCryst Pharmaceuticals Inc: Plans to Supply 19,125 Doses to Fulfill This Option Between Now and September 29, 2025
U.S. Government Awards BioCryst $69 Million RAPIVAB (Peramivir Injection) Contract for Strategic National Stockpile
Express News | U.S. Government Awards BioCryst $69 Million Rapivab® (Peramivir Injection) Contract for Strategic National Stockpile
Swelling Losses Haven't Held Back Gains for BioCryst Pharmaceuticals (NASDAQ:BCRX) Shareholders Since They're up 185% Over 5 Years
BioCryst and the Pan-Canadian Pharmaceutical Alliance (PCPA) Successfully Complete Negotiations for ORLADEYO (Berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals
Island Pharmaceuticals Signs Letteer of Intent to Acquire BioCryst's Antiviral Program
BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium